{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:39:20Z","timestamp":1790177960830,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.jaad.2009.05.042","type":"journal-article","created":{"date-parts":[[2010,2,13]],"date-time":"2010-02-13T04:24:27Z","timestamp":1266035067000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti\u2013interferon-alfa monoclonal antibody, in subjects with chronic\u00a0psoriasis"],"prefix":"10.1016","volume":"62","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy I.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiong","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.05.042_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0167-5699(86)90005-8","article-title":"Psoriasis: a disease of abnormal keratinocytes proliferation induced by T lymphocytes","volume":"7","author":"Valdimarrsson","year":"1986","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaad.2009.05.042_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2009.05.042_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2009.05.042_bib6","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2009.05.042_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaad.2009.05.042_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.1991.tb14774.x","article-title":"Psoriasis induced by interferon-alpha","volume":"125","author":"Funk","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/0001555573395","article-title":"Psoriasis exacerbation induced by interferon-alpha. Report of two cases","volume":"73","author":"Pauluzzi","year":"1993","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2009.05.042_bib10","first-page":"107","article-title":"Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B","volume":"15","author":"Ketikoglou","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.0022-202X.2003.22113.x","article-title":"In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered","volume":"122","author":"van der Fits","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jir.1994.14.229","article-title":"The type I interferon system is locally activated in psoriatic lesions","volume":"14","author":"Schmid","year":"1994","journal-title":"J Interferon Res"},{"key":"10.1016\/j.jaad.2009.05.042_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/43.1.7822763","article-title":"Expression of MxA protein in inflammatory dermatoses","volume":"43","author":"Fah","year":"1995","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jaad.2009.05.042_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.0022-202X.2004.22322.x","article-title":"Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers","volume":"122","author":"Suomela","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib16","doi-asserted-by":"crossref","first-page":"e2737","DOI":"10.1371\/journal.pone.0002737","article-title":"Type I interferon: Potential therapeutic target for psoriasis?","volume":"3","author":"Yao","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaad.2009.05.042_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.0022-202X.2005.23864.x","article-title":"Increased sensitivity to interferon-alpha in psoriatic T cells","volume":"125","author":"Eriksen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2009.05.042_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1074-7613(00)00064-9","article-title":"CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha\/beta signaling","volume":"13","author":"Hida","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2009.05.042_bib20","doi-asserted-by":"crossref","DOI":"10.4061\/2009\/374312","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti\u2013IFN-\u03b1 monoclonal antibody trials in systemic lupus erythematosus","author":"Yao","year":"2009","journal-title":"Human Genomics and\u00a0Proteomics"},{"key":"10.1016\/j.jaad.2009.05.042_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.jaad.2009.05.042_bib22","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2009.05.042_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ard.2006.063412","article-title":"Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients","volume":"66","author":"van der Pouw Kraan","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2009.05.042_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2008.03.016","article-title":"Interferons and scleroderma\u2014a new clue to understanding the pathogenesis of scleroderma?","volume":"118","author":"Coelho","year":"2008","journal-title":"Immunol Lett"},{"issue":"suppl 9","key":"10.1016\/j.jaad.2009.05.042_bib25","first-page":"S526","article-title":"MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus (abstract)","volume":"56","author":"Wallace","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2009.05.042_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2013oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2009.05.042_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-5945-5-13","article-title":"Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]","volume":"5","author":"Ortonne","year":"2005","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2009.05.042_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/SCT.2003.n.003","article-title":"Unique aspects of supportive care using monoclonal antibodies in cancer treatment","volume":"1","author":"Dillman","year":"2003","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.jaad.2009.05.042_bib30","doi-asserted-by":"crossref","first-page":"39765","DOI":"10.1074\/jbc.M102502200","article-title":"Interferon-kappa, a novel type I interferon expressed in human keratinocytes","volume":"276","author":"LaFleur","year":"2001","journal-title":"J Biol Chem"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209006860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209006860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:16:34Z","timestamp":1759270594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962209006860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0190962209006860"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.05.042","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2997965.2675063","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti\u2013interferon-alfa monoclonal antibody, in subjects with chronic\u00a0psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}